Abstract
目的
探讨线粒体钙单向转运体(MCU)在铅(Pb)暴露加重β淀粉样蛋白1-42(Aβ1-42)处理的小胶质细胞活化的作用,以揭示铅加重阿尔兹海默症(AD)样变的调控机制。
方法
将BV2细胞分为Control组(不予任何处理)、Aβ1-42组(10 μmol/L的Aβ1-42处理12 h)、Pb组(10 μmol/L铅处理细胞12 h)、Aβ1-42+Pb组(10 μmol/L的Aβ1-42处理1 h后加入10 μmol/L铅处理12 h)。ICP-MS检测BV2细胞的钙含量,相差显微镜观察BV2细胞的形态变化,细胞免疫荧光检测iNOS释放与氧化应激情况,Western blotting检测MCU蛋白表达量,CCK-8检测细胞活力。
结果
相比于Aβ1-42组,Aβ1-42+Pb组的细胞线粒体钙含量显著升高(P<0.001),MCU蛋白表达增多(P<0.05)。当下调MCU表达后,Pb与Aβ1-42联合处理的BV2细胞上清液对HT22细胞生长活力的损伤得到缓解(P>0.05)。铅与Aβ1-42联合处理可使BV2细胞活化,表现为胞体增大、突起增多,且Iba1与iNOS荧光信号均升高。下调MCU表达后,siMCU+Aβ1-42+Pb组的BV2细胞活化程度降低,显著缓解了氧化应激水平、线粒体钙超载及膜电位水平。
结论
铅暴露通过上调Aβ1-42处理的BV2细胞的MCU表达增加,使钙离子蓄积,引发氧化应激,加重了Aβ1-42处理的小胶质细胞活化引起的神经元损伤。
Keywords: 铅, 线粒体钙单向转运体, 线粒体钙, β淀粉样蛋白1-42, 小胶质细胞活化
Abstract
Objective
To investigate the role of mitochondrial calcium uniporter (MCU) in lead (Pb)‑potentiated microglial activation induced by amyloid β‑protein (1-42) (Aβ1-42) and the regulatory mechanism by which Pb exacerbates Alzheimer disease (AD)-like pathology.
Methods
Cultured BV2 cells treated with 10 μmol/L Aβ1-42 for 12 h (Aβ1-42 group), 10 μmol/L Pb for 12 h (Pb group), or 10 μmol/L Aβ1-42 for 1 h followed by 10 μmol/L Pb for 12 h (Aβ1-42+Pb group) were examined for changes in intracellular calcium levels using ICP-MS. Morphological changes of the treated cells were observed, and iNOS release and oxidative stress were assessed with immunofluorescence staining. The changes in cellular MCU protein expression was determined with Western blotting, and cell viability was evaluated using CCK-8 assay.
Results
Compared with Aβ1-42-treated cells, the cells with the combined treatment showed significantly elevated mitochondrial Ca²⁺ content and increased MCU protein expression. Downregulation of MCU expression obviously alleviated the reduction of viability of HT22 cells treated with the supernatant from BV2 cells co-treated with Pb and Aβ1-42. The combined treatment with lead and Aβ1-42 caused activation of BV2 cells, manifested by increased cell volume and number of protrusions and intensified fluorescence signals of both Iba1 and iNOS. Downregulation of MCU expression significantly suppressed activation of BV2 cells in the siMCU+Aβ1-42+Pb group, and obviously lowered oxidative stress level, mitochondrial calcium overload, and membrane potential level in the cells.
Conclusion
Pb exposure exacerbates neuronal injury mediated by Aβ1-42-activated microglia through upregulation of MCU expression, which causes mitochondrial calcium accumulation to trigger oxidative stress.
Keywords: lead (Pb), mitochondrial calcium uniporter, mitochondrial calcium, Aβ1-42 , microglial activation
铅(Pb)是一种典型的环境重金属污染物,可通过空气、水、土壤等途径进入人体,对人体多个系统造成损害[1]。因其蓄积性强、半衰期长,一旦进入机体,铅即可通过血脑屏障(BBB)长期滞留在中枢神经系统内,成为诱发神经退行性变的重要危险因子[2]。铅的神经毒性机制复杂,可使小胶质细胞活化[3],产生氧化应激[4],并引发持续的神经炎症[5];引发大脑中的线粒体功能障碍[6];直接损伤神经元,导致突触可塑性受损。另外,慢性铅暴露已被证实是阿尔兹海默症(AD)的重要环境风险因素[7-9],低剂量的铅暴露可通过血脑屏障加重小鼠AD的进展[10]。
AD是最常见的神经退行性疾病,临床上表现为不可逆的记忆减退和认知功能损害[11]。随着全球人口老龄化进程加剧,AD的患病率持续上升,成为越来越严重的社会问题[12]。AD病程较长,且发病机制复杂,而小胶质细胞的激活是AD进程的重要环节[13]。小胶质细胞作为中枢神经系统的固有免疫细胞,在AD的病理进程中扮演双重角色。在AD早期,小胶质细胞通过吞噬Aβ发挥神经保护作用[14];但随着病程进展,Aβ的持续刺激会导致小胶质细胞过度活化,释放细胞因子、产生活性氧,从而加剧神经炎症[15]。另外,AD患者大脑中金属稳态失衡普遍存在[16-18],这与Aβ沉积、小胶质细胞的激活、神经元损伤以及神经炎症相关。其中,AD的发病与Ca2+稳态失衡密切相关。
线粒体Ca2+稳态对于维持正常细胞能量代谢和信号转导至关重要,线粒体钙单向转运体(MCU)是调控Ca2+从胞浆到线粒体基质的重要通道,它可以通过调节线粒体膜对Ca2+的通透性来影响细胞内Ca2+的调节[19]。研究表明,载脂蛋白E(APOE)作为AD最重要的遗传风险因子,可以通过增加MCU介导的Ca2+内流进而调控脂质代谢、免疫反应和细胞间分子运输,同时破坏正常神经元Ca2+稳态,干扰神经元与小胶质细胞之间的通讯[20]。铅暴露也会进一步加重细胞内的Ca2+稳态失衡。一方面,铅可以模拟Ca2+信号,诱发细胞内游离Ca2+紊乱,干扰正常的Ca2+依赖性生理过程。研究表明,当海马体、纹状体和黑质中的铅浓度升高时,大脑的金属稳态被破坏,导致大脑黑质Ca2+水平显著升高[21]。另一方面,铅可以干扰Ca2+相关的信号通路。例如,铅可以使神经元细胞内Ca2+浓度升高,进而抑制CaMKII/CREB信号通路,同时激活Erk/Bcl2凋亡信号通路的激活,进一步诱导大鼠的神经退行性认知障碍[22]。然而既往主流研究关注于细胞质的Ca2+稳态变化,但未深入探讨其细胞的Ca2+转运机制;且在小胶质细胞中,铅通过Ca2+紊乱加重AD损伤的相关机制尚不明确。因此,为明确MCU是否参与铅暴露加重AD进程以及具体机制,本研究将通过构建小胶质细胞AD模型,阐明铅暴露是否通过调控MCU表达与功能,加剧线粒体Ca2+超载、氧化应激及神经炎症,为理解环境重金属暴露加重AD的分子机制提供新的实验依据。
1. 材料和方法
1.1. 仪器和材料
相差显微镜(Olympus, IX700),电感耦合等离子质谱仪(Thermo Fisher, USA),Odyssey双色红外荧光扫描成像系统(LiCor),激光共聚焦显微镜(Olympus, IX700),酶标仪(Molecular Devices)。Aβ1-42(中肽),六氟异丙醇(Macklin),二甲基亚砜(Biofroxx),DMEM高糖培养液、FBS(Gibco),CCK8试剂盒(日本同仁),活性氧检测试剂盒(Solarbio),Iba1抗体、iNOS抗体、MCU抗体(CST),GAPDH抗体(Proteintech)。本实验使用的小鼠小胶质瘤细胞系BV2细胞是由山东大学公共卫生学院赵秀兰教授赠予,小鼠海马神经元HT22神经元细胞购买自中国科学院细胞库。
1.2. Aβ1-42寡聚体配置
将1 mg Aβ1-42粉末用220 μL六氟异丙醇溶解并静置1 h。挥发过夜,形成透明的Aβ肽膜。用二甲基亚砜重新溶解并制成5 mmol/L Aβ1-42合成肽,使用PBS稀释成100 μmol/L浓度后4 ℃静置24 h。使用4 ℃离心机14 000 r/min离心10 min,取上清液,得到Aβ1-42寡聚体母液,分装后于-80 ℃保存。
1.3. 细胞培养与分组
1.3.1. 细胞培养与传代
本实验使用含有10%FBS的DMEM完全培养基,于含5% CO2的细胞恒温培养箱,37 ℃恒温培养细胞。每天定期换液,并观察细胞生长密度,生长密度达80%~90%时,使用胰蛋白酶消化并进行细胞传代。
1.3.2. 细胞染毒与分组处理
孵育BV2细胞至贴壁24 h后,观察细胞状态良好且密度为50%~60%,进行染毒处理。根据不同分组加入相应染毒试剂,并于含5% CO2,37 ℃的细胞恒温培养箱中培养。使用BV2小胶质细胞系,通过联合暴露于Aβ1-42和Pb构建体外AD细胞模型。实验分组为:Control组(不作处理);Aβ1-42组(10 μmol/L Aβ1-42处理细胞12 h);Pb组(10 μmol/L铅处理细胞12 h);Aβ1-42+Pb组(10 μmol/L Aβ1-42预处理1 h后加入10 μmol/L铅处理12 h)。
1.4. ICP-MS检测钙含量
取约50 mg组织样品于50 mL消化管中,加入2 mL浓硝酸与1 mL 30%过氧化氢,静置0.5~1 h。随后于110 ℃石墨消解炉中消解约6 h至组织完全溶解,升温至100 ℃开盖赶酸,再用超纯水定容至10 mL。经充分摇匀后,取1 mL溶液使用ICP-MS进行金属浓度检测。
1.5. 条件培养基制备及HT22细胞处理
将Control 组、Aβ1-42组、Pb组、Aβ1-42+Pb组的BV2细胞完成染毒处理12 h后,提取各皿的培养基,用4 ℃离心机500 g离心去除细胞碎片,收集得到条件培养基。将HT22细胞均匀接种于96孔板,恒温孵育24 h后,每孔加入200 μL含不同处理组受试物的条件培养基继续孵育12 h,后使用CCK-8试剂检测细胞活力。
1.6. CCK-8检测细胞活力
在96孔板中将细胞密度调整为5000~7000/孔,每组设置3个复孔。充分重悬并均匀地将细胞加入96孔板中,置于细胞恒温培养箱孵育24 h。随后根据实验目的配置好含药物的培养基,加入并孵育12 h。将药物处理12 h的细胞培养基吸出,加入10% CCK-8工作液,每孔100 μL于细胞培养箱中避光孵育1.5 h,于多功能酶标仪检测吸光度A 450 nm。独立实验重复3次。
1.7. 细胞形态学观察
BV2细胞处于对数生长期时,对细胞进行消化重悬并计数,将35 mm小皿的细胞密度设置为约2.2×105/皿,在药物处理12 h后,于相差显微镜下观察BV2细胞形态变化。
1.8. Western blotting检测细胞内MCU含量
使用含 1% 蛋白酶抑制剂及磷酸酶抑制剂混合液的 RIPA 裂解液(江苏凯基)提取 BV2 细胞总蛋白,以考马斯亮蓝G-250法(Bradford)在595 nm处测定蛋白浓度并配平。取等量蛋白经10%SDS-PAGE 分离后湿转至 PVDF 膜(Millipore),5% BSA 室温封闭1 h;随后加入兔抗MCU一抗(1∶500,CST),4 ℃ 孵育过夜。TBST洗膜3次后,以 IRDye 800CW Goat anti-Rabbit IgG(1∶10 000,LI-COR)室温避光孵育1 h,TBST 再次洗涤。使用 Odyssey 双色红外荧光扫描成像系统显影,ImageJ 6.0软件分析目标条带与内参GAPDH的灰度值,计算MCU相对表达量。
1.9. 免疫荧光检测胞内蛋白
将BV2细胞培养于Confocal玻底培养皿,用药物处理12 h。用预冷的PBS将药物处理好的Confocal培养皿清洗1遍,加入4%多聚甲醛室温固定细胞10 min,用PBS清洗3遍。使用1 mL冰甲醇在-20 ℃环境下进行通透处理15 min,加入配置好的5%BSA,覆盖培养皿中的细胞,并室温静置45 min,用PBS清洗3遍。使用抗体稀释液配制一抗Iba1(1∶150),iNOS(1∶150),β-Amyloid(1∶150),加入到培养皿中,放置于湿盒中4 ℃静置过夜,PBS清洗3遍。用甲醇现配的DAPI溶液(1∶20),避光室温静置5 min,无水甲醇清洗3遍。加入200 μL封闭液(PBS∶丙三醇=1∶1),4 ℃保存,于激光共聚焦显微镜下观察。
1.10. ROS检测
使用无血清DMEM培养基将DCFH-DA荧光探针配制成10 μmol/L浓度。弃去细胞培养上清,使用PBS清洗2次,加入1 mL荧光染料,于37 ℃恒温培养箱避光孵育20 min。使用无血清DMEM培养基清洗3次,488 nm激发波长处观察ROS荧光强度。
1.11. 线粒体钙离子浓度检测
使用DMEM将MitoTracker和Rhod-2AM配制成200 nmol/L和5 μmol/L预混液,标记线粒体及线粒体钙离子。弃去细胞上清,PBS清洗2次,加入1.5 mL预混液,避光孵育30 min,PBS清洗3次,分别在488 nm和594 nm激发波长观察线粒体钙离子浓度。
1.12. JC-1 检测线粒体膜电位
使用DMEM将JC-1配成10 μmol/L工作液,弃去细胞上清,PBS清洗2次,加入1 mL,避光孵育20 min,PBS清洗3次,分别在488 nm和594 nm激发波长观察线粒体膜电位。
1.13. MCU siRNA转染
将干扰序列冻干粉用125 μL DEPC水充分溶解混匀;按(125 μL Opti‑MEM + 4.5 μL Lipo3000)×1.1 的体积配制转染试剂预混液,在1.5 mL EP管中加入125 μL Opti‑MEM与 1.1 μL NC/siRNA 干扰序列溶液,再从预混液中吸取125 μL 加入该 EP 管,轻柔混匀后室温静置孵育,随后将转染复合物加入每皿含1.25 mL DMEM 完全培养基的 BV2 细胞中,混匀后继续培养。经过干扰处理的BV2细胞培养24 h后,按照上述各组染毒方法进行后续受试物处理。MCU siRNA干扰序列由苏州泓迅生物科技股份有限公司合成(表1)。
表1.
MCU siRNA干扰序列
Tab.1 MCU siRNA interference sequences
| Name | Sequence |
|---|---|
| siRNA-1 sense | 5' GGAGAAGGUACGAAUUGAAdTdT |
| siRNA-l antisense | 5' UUCAAUUCGUACCUUCUCCdTdT |
| siRNA-2 sense | 5' CCUUCCGGAACAAUAAAUAdTdT |
| siRNA-2 antisense | 5' UAUUUAUUGUUCCGGAAGGdTdT |
| siRNA-3 sense | 5' GAUUACCGGUGAUAUCUGUdTdT |
| siRNA-3 antisense | 5' ACAGAUAUCACCGGUAAUCdTdT |
1.14. 统计学分析
采用 SPSS 20.0软件进行统计学分析,使用Graphpad Prism 6.0软件作图。数据以均数±标准差表示,组间比较采用单因素方差分析,并根据方差齐性检验结果选择事后多重比较的方法进行组间比较,P<0.05认为差异有统计学意义。
2. 结果
2.1. 铅加重Aβ1-42处理的BV2细胞线粒体钙蓄积及MCU表达增多
相比Control组,Pb组、Aβ1-42+Pb组线粒体钙离子增多(P<0.001),Aβ1-42+Pb组线粒体钙离子较Aβ1-42组增多(P<0.001,图1A)。Rhod-2AM荧光染色结果显示,相比Aβ1-42组,Aβ1-42+Pb组的双染的荧光增多,说明铅处理加重了Aβ1-42处理的BV2细胞线粒体钙蓄积(图1B)。用Western blotting检测MCU蛋白表达量的结果显示,相比Aβ1-42组,Aβ1-42+Pb组的MCU蛋白表达增多(P<0.05,图1C)。
图1.

铅对Aβ1-42处理的BV2细胞线粒体钙蓄积及MCU蛋白表达的影响
Fig.1 Effects of lead on mitochondrial calcium accumulation and MCU protein expression in Aβ1 42 treated BV2 cells. A: ICP-MS detection of mitochondrial calcium concentration in BV2 cells. B: Rhod-2 AM fluorescence staining for detecting mitochondrial calcium ion concentration in BV2 cells. C: Western blotting for detecting MCU expression in BV2 cells (n=3). *P<0.05, ***P<0.05 vs control group; # P<0.05, ### P<0.001.
2.2. 敲低 MCU 缓解铅与Aβ1-42联合诱导BV2细胞介导的HT22细胞损伤
用干扰序列下调BV2细胞的MCU表达的结果显示,3条序列均可有效降低MCU的表达量(P<0.01),其中siRNA3序列的效果最为显著(P<0.001,图2A),后续实验采用siRNA3序列对MCU进行干扰处理。CCK8检测结果显示,与NC组相比,NC+Aβ+Pb组的BV2细胞上清液对HT22细胞产生损伤(P<0.05);而siMCU+Aβ+Pb组显示,干扰MCU之后铅与Aβ1-42联合处理的BV2细胞不会使HT22细胞生长活力受损(P>0.05,图2B)。
图2.

敲低MCU缓解铅与Aβ1-42联合处理的BV2细胞介导的HT22神经元损伤
Fig.2 Downregulation of MCU alleviates HT22 neuronal damage caused by BV2 cells with combined treatment with lead and Aβ1-42. A: Western blotting for analyzing efficiency for siRNA-mediated MCU silencing. B: CCK-8 assay for detecting the effect of conditioned medium from BV2 cells with combine treatment with Aβ1-42 and lead on viability of HT22 cells before and after MCU silencing (n=3). *P<0.01, **P<0.01, ***P<0.001 vs NC group.
2.3. 敲低MCU可缓解铅与Aβ1-42联合处理的BV2细胞活化
通过对MCU进行敲低处理后,相差显微镜观察发现NC+Aβ+Pb组BV2细胞出现胞体增大、突出增粗增多等形态改变,敲低MCU可以显著缓解铅与Aβ1-42联合处理的BV2细胞活化表现(图3A);免疫荧光标记Iba1与iNOS,相比NC+Aβ+Pb组,siMCU+Aβ+Pb组的荧光强度减弱(图3B、C)。
图3.

敲低MCU可缓解铅与Aβ1-42联合处理的BV2细胞活化
Fig.3 Downregulation of MCU alleviates activation of BV2 cells treated with both lead and Aβ1-42. A: Morphological changes of BV2 cells before and after MCU interference. B: Immunofluorescence labeling of Iba1 for observing activation of microglial cells before and after MCU interference. C: Immunofluorescence staining for observing expression of iNOS in cells before and after MCU interference.
2.4. 敲低MCU可缓解铅与Aβ1-42联合处理的BV2细胞氧化应激
DCFH-DA荧光探针检测铅与Aβ1-42联合处理的细胞氧化应激结果显示,NC+Aβ+Pb组荧光强度均显著升高,而siMCU+Aβ+Pb的ROS荧光强度减弱(图4)。
图4.

干扰MCU可缓解铅与Aβ1-42联合处理的BV2细胞氧化应激
Fig.4 Downregulation of MCU alleviates oxidative stress in BV2 cells treated with both lead and Aβ1-42, shown by lowered by ROS level detected using DCFH-DA fluorescence labeling.
2.5. 敲低MCU可缓解铅与Aβ1-42联合处理的BV2细胞线粒体钙蓄积及膜电位下降
Rhod-2AM 荧光染色结果显示,NC+Aβ+Pb组红色荧光强度增强,而siMCU+Aβ+Pb组中的BV2细胞红色荧光强度减弱(图5A)。
图5.

敲低MCU缓解铅与Aβ1-42联合处理的BV2细胞线粒体钙蓄积增加及膜电位下降
Fig.5 Downregulation of MCU alleviates mitochondrial calcium accumulation and mitochondrial membrane potential reduction in BV2 cells treated with both lead and Aβ1-42. A: Rhod-2 AM fluorescence staining for detecting mitochondrial calcium ion concentration of BV2 cells. B: JC-1 fluorescence labeling for detecting mitochondrial membrane potential.
JC-1荧光染色检测结果表明,NC+Aβ+Pb组出现绿色单体荧光强度升高,膜电位降低,而siMCU+Aβ+Pb组绿色单体荧光强度减弱(图5B)。
3. 讨论
在AD病理过程中,Aβ1-42可与小胶质细胞表面受体相结合,激活小胶质细胞并诱发神经炎症反应[23]。因此,目前已有大量研究通过Aβ1-42寡聚体诱导小胶质细胞活化以构建AD细胞模型[24-26]。Dou等[27]系统评估了处理时间及不同浓度的Aβ1-42对BV2细胞的影响,发现处理时间达20 h以上会显著降低细胞存活率,且细胞存活率随浓度越高而降低。本课题组前期研究[28]在此基础上进一步扩大浓度范围进行验证,发现浓度为10 μmol/L的Aβ1-42处理12 h可以有效激活小胶质细胞,并不影响其细胞活力。基于以上发现,本实验最终确定10 μmol/L Aβ1-42处理BV2细胞12 h作为造模的处理条件。
长期慢性铅暴露不仅与儿童认知发育障碍相关,也被认为是多种神经退行性疾病的重要环境风险因素[29]。近年来,许多研究显示血铅可以影响钙离子稳态失衡。人体血铅水平的升高可通过影响体内钙离子稳态失衡来扰乱细胞的生物代谢,导致出现智商下降、学习困难、注意力缩短等问题[30]。课题组前期研究也显示,铅暴露会加剧Aβ1-42处理后的BV2细胞的活化,引起TNF-α和 IL-6 的表达水平升高和细胞形态的改变[31]。基于上述研究,本研究进一步使用ICP-MS检测,发现铅暴露后BV2细胞的钙离子含量显著升高,并引起BV2细胞的线粒体钙蓄积。
研究显示,家族性的AD患者中观察到钙离子稳态失衡早于斑块沉积和神经纤维缠结等典型病理改变出现[32]。而MCU是维持钙离子稳态的关键因素,为了探究MCU是否参与铅加重及Aβ1-42处理的BV2细胞活化,于是我们提取了不同组别的BV2细胞蛋白进行Western blotting检测,结果发现铅暴露会引起Aβ1-42处理的小胶质细胞的MCU的表达上调。在镉诱导的肝毒性研究中,Liu等[33]也观察到MCU表达上调的现象,并且发现MCU可能通过泛素化过度激活线粒体自噬,导致细胞损伤。这说明MCU上调可能是多种环境重金属诱导细胞损伤的共同机制。
近期研究表明,敲低了海马区神经元MCU能有效改善AD小鼠学习和记忆能力[34]。为了验证MCU在细胞层面的作用,通过干扰MCU的表达,我们发现其降低了小胶质细胞的活化信号,减轻了小胶质细胞的氧化应激水平,并缓解了对HT22海马神经元的损伤,说明MCU在铅加重AD病理进展中起到重要的作用。Yang等[35]在人类神经母细胞瘤SH-SY5Y细胞的实验中,同样验证了MCU的过表达可放大Pb诱导的ROS升高,提示可能通过调控线粒体钙离子的吸收,保护铅诱导的氧化应激。Cai等[36]通过Aβ和冈田酸(Okadaic acid)构建HT22神经元细胞的AD模型,同样对其MCU表达进行敲低,恢复了HT22细胞存活率降低,降低了其氧化应激及钙超载水平。此外,神经元与小胶质细胞之间存在双向调控机制。二者可以通过谷氨酸、GABA等神经递质进行信号交互 [37];而小胶质细胞也可通过释放含有促炎因子、Aβ、miRNA的细胞外囊泡,这些囊泡被神经元摄取后可引起突触功能障碍,进而影响神经元功能[38, 39]。本研究发现,干扰MCU表达后,以BV2细胞的条件培养基处理HT22海马神经元,可使神经元的损伤明显减轻,提示了小胶质细胞中由MCU介导的线粒体钙稳态变化能显著影响AD中小胶质细胞相关的神经元损害。
线粒体钙离子的过量蓄积可诱导线粒体膜电位下降,引起线粒体功能障碍[40]。本研究中发现,在敲低MCU表达后,铅暴露引起的膜电位下降得到显著缓解,线粒体功能得到一定程度上的恢复。因此,靶向MCU治疗恢复线粒体功能,从而缓解小胶质细胞氧化应激,改善神经元活动,可能是潜在预防和治疗AD的有效干预措施策略。
综上所述,铅暴露可通过上调小胶质细胞中MCU的表达,诱导线粒体钙蓄积与氧化应激,从而驱动其炎症激活并最终导致海马神经元损伤。然而,本研究虽观察了铅暴露下Aβ1-42处理的小胶质细胞线粒体钙蓄积现象及其下游效应,但本研究尚未涉及胞浆钙信号的实时监测,因此无法明确线粒体钙超载与MCU表达上调之间的因果关系;且本研究仅在细胞上使用敲低MCU基因表达,仍需后续进一步动物实验验证。
基金资助
国家自然科学基金(82473665);广东省自然科学基金(2024A1515012722)
Supported by National NaturalScience Foundation of China (82473665).
参考文献
- 1. Yang JB, Li X, Xiong ZH, et al. Environmental pollution effect analysis of lead compounds in China based on life cycle[J]. Int J Environ Res Public Health, 2020, 17(7): 2184. doi: 10.3390/ijerph17072184 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Li C, Shi L, Wang YB, et al. High-fat diet exacerbates lead-induced blood–brain barrier disruption by disrupting tight junction integrity[J]. Environ Toxicol, 2021, 36(7): 1412-21. doi: 10.1002/tox.23137 [DOI] [PubMed] [Google Scholar]
- 3. Zhu JW, Zhou F, Zhou Q, et al. NLRP3 activation in microglia contributes to learning and memory impairment induced by chronic lead exposure in mice[J]. Toxicol Sci, 2023, 191(1): 179-91. doi: 10.1093/toxsci/kfac115 [DOI] [PubMed] [Google Scholar]
- 4. Lee JW, Choi H, Hwang UK, et al. Toxic effects of lead exposure on bioaccumulation, oxidative stress, neurotoxicity, and immune responses in fish: a review[J]. Environ Toxicol Pharmacol, 2019, 68: 101-8. doi: 10.1016/j.etap.2019.03.010 [DOI] [PubMed] [Google Scholar]
- 5. Chibowska K, Korbecki J, Gutowska I, et al. Pre- and neonatal exposure to lead (Pb) induces neuroinflammation in the forebrain cortex, hippocampus and cerebellum of rat pups[J]. Int J Mol Sci, 2020, 21(3): 1083. doi: 10.3390/ijms21031083 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Maiti AK, Saha NC, More SS, et al. Neuroprotective efficacy of mitochondrial antioxidant MitoQ in suppressing peroxynitrite-mediated mitochondrial dysfunction inflicted by lead toxicity in the rat brain[J]. Neurotox Res, 2017, 31(3): 358-72. doi: 10.1007/s12640-016-9692-7 [DOI] [PubMed] [Google Scholar]
- 7. Bihaqi SW, Zawia NH. Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb)[J]. NeuroToxicology, 2013, 39: 95-101. doi: 10.1016/j.neuro.2013.07.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Jaafarzadeh M, Mahjoob Khaligh R, Mohsenifar Z, et al. Protecting effects of N-acetyl cysteine supplementation against lead and cadmium-induced brain toxicity in rat models[J]. Biol Trace Elem Res, 2022, 200(10): 4395-403. doi: 10.1007/s12011-021-03034-0 [DOI] [PubMed] [Google Scholar]
- 9. Choi J, Kim YS, Kim MH, et al. Maternal lead exposure induces sex-dependent cerebellar glial alterations and repetitive behaviors[J]. Front Cell Neurosci, 2022, 16: 954807. doi: 10.3389/fncel.2022.954807 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Wu S, Liu HX, Zhao HP, et al. Environmental lead exposure aggravates the progression of Alzheimer's disease in mice by targeting on blood brain barrier[J]. Toxicol Lett, 2020, 319: 138-47. doi: 10.1016/j.toxlet.2019.11.009 [DOI] [PubMed] [Google Scholar]
- 11. Lane CA, Hardy J, Schott JM. Alzheimer's disease[J]. Eur J Neurol, 2018, 25(1): 59-70. doi: 10.1111/ene.13439 [DOI] [PubMed] [Google Scholar]
- 12. Ren RJ, Qi JL, Lin SH, et al. The China Alzheimer report 2022[J]. Gen Psychiatry, 2022, 35(1): e100751. doi: 10.1136/gpsych-2022-100751 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Pascoal TA, Benedet AL, Ashton NJ, et al. Microglial activation and tau propagate jointly across Braak stages[J]. Nat Med, 2021, 27(9): 1592-9. doi: 10.1038/s41591-021-01456-w [DOI] [PubMed] [Google Scholar]
- 14. Huat TJ, Camats-Perna J, Newcombe EA, et al. Metal toxicity links to Alzheimer's disease and neuroinflammation[J]. J Mol Biol, 2019, 431(9): 1843-68. doi: 10.1016/j.jmb.2019.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Dinkins MB, Dasgupta S, Wang GH, et al. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2014, 35(8): 1792-800. doi: 10.1016/j.neurobiolaging.2014.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Smith AN, Shaughness M, Collier S, et al. Therapeutic targeting of microglia mediated oxidative stress after neurotrauma[J]. Front Med, 2022, 9: 1034692. doi: 10.3389/fmed.2022.1034692 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Wang L, Yin YL, Liu XZ, et al. Current understanding of metal ions in the pathogenesis of Alzheimer's disease[J]. Transl Neurodegener, 2020, 9(1): 10. doi: 10.1186/s40035-020-00189-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Rahman MA, Rahman MS, Uddin MJ, et al. Emerging risk of environmental factors: insight mechanisms of Alzheimer's diseases[J]. Environ Sci Pollut Res, 2020, 27(36): 44659-72. doi: 10.1007/s11356-020-08243-z [DOI] [PubMed] [Google Scholar]
- 19. Calvo-Rodriguez M, Bacskai BJ. Mitochondria and calcium in Alzheimer's disease: from cell signaling to neuronal cell death[J]. Trends Neurosci, 2021, 44(2): 136-51. doi: 10.1016/j.tins.2020.10.004 [DOI] [PubMed] [Google Scholar]
- 20. Wang MH, Zhang H, Liang JL, et al. Calcium signaling hypothesis: a non-negligible pathogenesis in Alzheimer's disease[J]. J Adv Res, 2025, 77: 513-34. doi: 10.1016/j.jare.2025.01.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Li ZC, Zhao YS, Lin JJ, et al. Sodium para-aminosalicylic acid ameliorates brain neuroinflammation and behavioral deficits in juvenile lead-exposed rats by modulating MAPK signaling pathway and alpha-synuclein[J]. Toxicol Lett, 2023, 375: 48-58. doi: 10.1016/j.toxlet.2022.12.013 [DOI] [PubMed] [Google Scholar]
- 22. Zhou FK, Du GH, Xie J, et al. RyRs mediate lead-induced neurodegenerative disorders through calcium signaling pathways[J]. Sci Total Environ, 2020, 701: 134901. doi: 10.1016/j.scitotenv.2019.134901 [DOI] [PubMed] [Google Scholar]
- 23. Reed-Geaghan EG, Savage JC, Hise AG, et al. CD14 and toll-like receptors 2 and 4 are required for fibrillar aβ-stimulated microglial activation[J]. J Neurosci, 2009, 29(38): 11982-92. doi: 10.1523/jneurosci.3158-09.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. 邓 婷, 余志杰, 徐 颖, 等. AD细胞模型的建立及评价方法研究进展[J]. 中国药理学通报, 2020, 36(4): 470-5. doi: 10.3969/j.issn.1001-1978.2020.04.004 [DOI] [Google Scholar]
- 25. Heshmati-Fakhr N, Sotoodehnejadnematalahi F, Yousefi N, et al. Triggering microglia through toll-like receptor 2 pathway induced interferon β expression in cell and animal model of Alzheimer's disease[J]. NeuroReport, 2018, 29(17): 1456-62. [LinkOut]. doi: 10.1097/wnr.0000000000001132 [DOI] [PubMed] [Google Scholar]
- 26. Xiong JX, Wang CZ, Chen HY, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway[J]. Int J Neurosci, 2014, 124(8): 609-20. doi: 10.3109/00207454.2013.865027 [DOI] [PubMed] [Google Scholar]
- 27. Dou RX, Zhang YM, Hu XJ, et al. Aβ1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4[J]. Redox Biol, 2024, 78: 103428. doi: 10.1016/j.redox.2024.103428 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. 陈丽旋, 黄定帮, 郑 刚, 等. 铅暴露加重 Aβ1-42 处理的小胶质细胞活化和小胶质细胞中的铜离子蓄积[J]. 南方医科大学学报, 2023, 43(10): 1752-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Bakulski KM, Rozek LS, Dolinoy DC, et al. Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics[J]. Curr Alzheimer Res, 2012, 9(5): 563-73. doi: 10.2174/156720512800617991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Olufemi AC, Mji A, Mukhola MS. Potential health risks of lead exposure from early life through later life: implications for public health education[J]. Int J Environ Res Public Health, 2022, 19(23): 16006. doi: 10.3390/ijerph192316006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Huang DB, Chen LX, Ji QY, et al. Lead aggravates Alzheimer's disease pathology via mitochondrial copper accumulation regulated by COX17[J]. Redox Biol, 2024, 69: 102990. doi: 10.1016/j.redox.2023.102990 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Schrank S, Barrington N, Stutzmann GE. Calcium-handling defects and neurodegenerative disease[J]. Cold Spring Harb Perspect Biol, 2020, 12(7): a035212. doi: 10.1101/cshperspect.a035212 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Liu C, Li HJ, Duan WX, et al. MCU upregulation overactivates mitophagy by promoting VDAC1 dimerization and ubiquitination in the hepatotoxicity of cadmium[J]. Adv Sci, 2023, 10(7): 2203869. doi: 10.1002/advs.202203869 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Cai H Y, Qiao J, Chen S R, et al. [Mitochondrial calcium uniporter knockdown in hippocampal neurons improved the learning and memory dysfunction of Alzheimer's disease mice [J]. Sheng li xue bao : [Acta physiologica Sinica], 2022, 74(5): 715-25. [PubMed] [Google Scholar]
- 35. Yang XY, Wang B, Zeng HQ, et al. Role of the mitochondrial Ca2+ uniporter in Pb2+-induced oxidative stress in human neuroblastoma cells[J]. Brain Res, 2014, 1575: 12-21. doi: 10.1016/j.brainres.2014.05.032 [DOI] [PubMed] [Google Scholar]
- 36. Cai HY, Hou F, Wang Y, et al. Mitochondrial Calcium Uniporter knockdown improves the viability of HT22 hippocampal neurons in Alzheimer’s disease[J]. Eur J Pharmacol, 2025, 991: 177347. doi: 10.1016/j.ejphar.2025.177347 [DOI] [PubMed] [Google Scholar]
- 37. Czapski GA, Strosznajder JB. Glutamate and GABA in microglia-neuron cross-talk in Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(21): 11677. doi: 10.3390/ijms222111677 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Paolicelli RC, Bergamini G, Rajendran L. Cell-to-cell communication by extracellular vesicles: focus on microglia[J]. Neuroscience, 2019, 405: 148-57. doi: 10.1016/j.neuroscience.2018.04.003 [DOI] [PubMed] [Google Scholar]
- 39. Gabrielli M, Prada I, Joshi P, et al. Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer's disease[J]. Brain, 2022, 145(8): 2849-68. doi: 10.1093/brain/awac083 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Guo CY, Sun L, Chen XP, et al. Oxidative stress, mitochondrial damage and neurodegenerative diseases[J]. Neural Regen Res, 2013, 8(21): 2003-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
